Literature DB >> 32568215

Microglia complement astrocytes in neuromyelitis optica.

Zahra Moinfar, Scott S Zamvil.   

Abstract

Neuromyelitis optica (NMO) is a central nervous system (CNS) inflammatory autoimmune disease caused by antibodies against aquaporin-4 (AQP4) expressed on astrocytes. Binding of AQP4-specific antibodies (NMO-IgG) triggers activation of the complement cascade, which is responsible for astrocyte loss and secondary demyelination. Although the role for the cytolytic complement proteins in astrocyte destruction in NMO is well established, little is known regarding the initial phase of astrocyte injury. In this issue of the JCI, Chen and colleagues evaluated the precytolytic phase when NMO-IgG binds astrocytes in vivo in the absence of exogenous complement. NMO-IgG alone caused astrocyte activation and AQP4 loss. Surprisingly, microglia, CNS-resident innate immune cells that produce endogenous complement, were required for clinical manifestations of disease, a finding that suggests microglia may serve as a therapeutic target in NMO.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32568215      PMCID: PMC7410041          DOI: 10.1172/JCI138804

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  22 in total

1.  Changes in the Synaptic Proteome in Tauopathy and Rescue of Tau-Induced Synapse Loss by C1q Antibodies.

Authors:  Borislav Dejanovic; Melanie A Huntley; Ann De Mazière; William J Meilandt; Tiffany Wu; Karpagam Srinivasan; Zhiyu Jiang; Vineela Gandham; Brad A Friedman; Hai Ngu; Oded Foreman; Richard A D Carano; Ben Chih; Judith Klumperman; Corey Bakalarski; Jesse E Hanson; Morgan Sheng
Journal:  Neuron       Date:  2018-11-01       Impact factor: 17.173

2.  Neurotoxic reactive astrocytes are induced by activated microglia.

Authors:  Shane A Liddelow; Kevin A Guttenplan; Laura E Clarke; Frederick C Bennett; Christopher J Bohlen; Lucas Schirmer; Mariko L Bennett; Alexandra E Münch; Won-Suk Chung; Todd C Peterson; Daniel K Wilton; Arnaud Frouin; Brooke A Napier; Nikhil Panicker; Manoj Kumar; Marion S Buckwalter; David H Rowitch; Valina L Dawson; Ted M Dawson; Beth Stevens; Ben A Barres
Journal:  Nature       Date:  2017-01-18       Impact factor: 49.962

3.  Inhibitor(s) of the classical complement pathway in mouse serum limit the utility of mice as experimental models of neuromyelitis optica.

Authors:  Julien Ratelade; A S Verkman
Journal:  Mol Immunol       Date:  2014-06-28       Impact factor: 4.407

4.  Astrocyte-microglia interaction drives evolving neuromyelitis optica lesion.

Authors:  Tingjun Chen; Vanda A Lennon; Yong U Liu; Dale B Bosco; Yujiao Li; Min-Hee Yi; Jia Zhu; Shihui Wei; Long-Jun Wu
Journal:  J Clin Invest       Date:  2020-08-03       Impact factor: 14.808

5.  Membrane assembly of aquaporin-4 autoantibodies regulates classical complement activation in neuromyelitis optica.

Authors:  John Soltys; Yiting Liu; Alanna Ritchie; Scott Wemlinger; Kristin Schaller; Hannah Schumann; Gregory P Owens; Jeffrey L Bennett
Journal:  J Clin Invest       Date:  2019-04-08       Impact factor: 14.808

6.  Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.

Authors:  Sean J Pittock; Achim Berthele; Kazuo Fujihara; Ho Jin Kim; Michael Levy; Jacqueline Palace; Ichiro Nakashima; Murat Terzi; Natalia Totolyan; Shanthi Viswanathan; Kai-Chen Wang; Amy Pace; Kenji P Fujita; Róisín Armstrong; Dean M Wingerchuk
Journal:  N Engl J Med       Date:  2019-05-03       Impact factor: 91.245

7.  A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica.

Authors:  Claudia F Lucchinetti; Raul N Mandler; Dorian McGavern; Wolfgang Bruck; Gerald Gleich; Richard M Ransohoff; Corinna Trebst; Brian Weinshenker; Dean Wingerchuk; Joseph E Parisi; Hans Lassmann
Journal:  Brain       Date:  2002-07       Impact factor: 13.501

Review 8.  The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica.

Authors:  Claudia F Lucchinetti; Yong Guo; Bogdan F Gh Popescu; Kazuo Fujihara; Yasuto Itoyama; Tatsuro Misu
Journal:  Brain Pathol       Date:  2014-01       Impact factor: 6.508

Review 9.  Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?

Authors:  Scott S Zamvil; Anthony J Slavin
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-01-22

10.  C1q-targeted monoclonal antibody prevents complement-dependent cytotoxicity and neuropathology in in vitro and mouse models of neuromyelitis optica.

Authors:  Puay-Wah Phuan; Hua Zhang; Nithi Asavapanumas; Michael Leviten; Arnon Rosenthal; Lukmanee Tradtrantip; A S Verkman
Journal:  Acta Neuropathol       Date:  2013-05-16       Impact factor: 15.887

View more
  3 in total

Review 1.  The role and mechanisms of Microglia in Neuromyelitis Optica Spectrum Disorders.

Authors:  Wenqun Li; Jiaqin Liu; Wei Tan; Yedi Zhou
Journal:  Int J Med Sci       Date:  2021-06-16       Impact factor: 3.738

2.  Case Report: Interferon-Alpha-Induced Neuromyelitis Optica Spectrum Disorder.

Authors:  Jie Rao; Na Xu; Jing Sun; Yan Li; Fangwang Fu
Journal:  Front Neurol       Date:  2022-04-25       Impact factor: 4.003

Review 3.  Neuromyelitis Optica Spectrum Disorder: From Basic Research to Clinical Perspectives.

Authors:  Tzu-Lun Huang; Jia-Kang Wang; Pei-Yao Chang; Yung-Ray Hsu; Cheng-Hung Lin; Kung-Hung Lin; Rong-Kung Tsai
Journal:  Int J Mol Sci       Date:  2022-07-18       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.